Lucid Diagnostics Stock Beneish M Score

LUCD Stock  USD 1.34  0.14  9.46%   
This module uses fundamental data of Lucid Diagnostics to approximate the value of its Beneish M Score. Lucid Diagnostics M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Check out Lucid Diagnostics Piotroski F Score and Lucid Diagnostics Altman Z Score analysis.
For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.
  
At present, Lucid Diagnostics' Interest Debt Per Share is projected to increase slightly based on the last few years of reporting. The current year's Debt To Assets is expected to grow to 0.53, whereas Short and Long Term Debt Total is forecasted to decline to about 9.5 M. At present, Lucid Diagnostics' ROE is projected to increase significantly based on the last few years of reporting. The current year's Net Debt To EBITDA is expected to grow to 0.07, whereas PTB Ratio is forecasted to decline to (24.08).
At this time, Lucid Diagnostics' M Score is unavailable. The earnings manipulation may begin if Lucid Diagnostics' top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Lucid Diagnostics executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Lucid Diagnostics' earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-5.04
Beneish M Score - Unavailable
Elasticity of Receivables

1.23

Focus
Asset Quality

1.69

Focus
Expense Coverage

0.56

Focus
Gross Margin Strengs

1.05

Focus
Accruals Factor

0.56

Focus
Depreciation Resistance

0.83

Focus
Net Sales Growth

1.05

Focus
Financial Leverage Condition

1.23

Focus

Lucid Diagnostics Beneish M-Score Indicator Trends

The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Lucid Diagnostics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
Current ValueLast YearChange From Last Year 10 Year Trend
Net Receivables52.4 K40.5 K
Significantly Up
Slightly volatile
Total Assets26.8 M31.4 M
Fairly Down
Slightly volatile
Total Current Assets19.4 M25.4 M
Way Down
Slightly volatile
Non Current Assets Total3.6 MM
Way Down
Slightly volatile
Property Plant Equipment1.4 M1.8 M
Significantly Down
Slightly volatile
Depreciation And Amortization2.7 M2.2 M
Fairly Up
Slightly volatile
Selling General Administrative13.1 M22.1 M
Way Down
Slightly volatile
Total Current Liabilities35.5 M33.8 M
Sufficiently Up
Slightly volatile
Non Current Liabilities Total170.1 K179.1 K
Notably Down
Pretty Stable
Short Term Debt8.8 M17.3 M
Way Down
Slightly volatile
Short Term Investments1.6 M1.5 M
Sufficiently Up
Slightly volatile

Lucid Diagnostics Beneish M-Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Lucid Diagnostics' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Lucid Diagnostics in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Lucid Diagnostics' degree of accounting gimmicks and manipulations.

About Lucid Diagnostics Beneish M Score

M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.

Depreciation And Amortization

2.74 Million

At present, Lucid Diagnostics' Depreciation And Amortization is projected to decrease significantly based on the last few years of reporting.

Lucid Diagnostics Earnings Manipulation Drivers

Although earnings manipulation is typically not the result of intentional misconduct by the c-level executives, it is still a widespread practice by the senior management of public companies such as Lucid Diagnostics. It is usually done by a series of misrepresentations of various accounting rules and operating activities across multiple financial cycles. The best way to spot the manipulation is to examine the historical financial statement to find inconsistencies in earning reports to find trends in assets or liabilities that are not sustainable in the future.
202020212022202320242025 (projected)
Total Assets2.2M59.0M32.5M27.3M31.4M26.8M
Total Current Assets1.4M57.3M24.4M22.1M25.4M19.4M
Non Current Assets Total755K1.7M8.2M5.2M6.0M3.6M
Depreciation And Amortization8.3M4K1.9M2.5M2.2M2.7M
Selling General Administrative2.8M12.8M23.7M19.3M22.1M13.1M
Total Current Liabilities15.7M4.3M8.4M29.4M33.8M35.5M
Non Current Liabilities Total2.1M2.8B1.0M199K179.1K170.1K
Net Debt(111.3K)(53.7M)(20.5M)(3.6M)(3.3M)(3.4M)
Operating Income(8.3M)(27.4M)(56.2M)(48.5M)(43.6M)(45.8M)
Total Cash From Operating Activities(5.6M)(17.7M)(29.7M)(32.8M)(29.5M)(28.1M)
Investments(10.3K)(862K)(4.1M)(249K)(224.1K)(235.3K)

About Lucid Diagnostics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Lucid Diagnostics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lucid Diagnostics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lucid Diagnostics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Lucid Diagnostics is a strong investment it is important to analyze Lucid Diagnostics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Lucid Diagnostics' future performance. For an informed investment choice regarding Lucid Stock, refer to the following important reports:
Check out Lucid Diagnostics Piotroski F Score and Lucid Diagnostics Altman Z Score analysis.
For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.
You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lucid Diagnostics. If investors know Lucid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lucid Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.12)
Revenue Per Share
0.09
Quarterly Revenue Growth
0.497
Return On Assets
(1.01)
Return On Equity
(10.08)
The market value of Lucid Diagnostics is measured differently than its book value, which is the value of Lucid that is recorded on the company's balance sheet. Investors also form their own opinion of Lucid Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Lucid Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lucid Diagnostics' market value can be influenced by many factors that don't directly affect Lucid Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lucid Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lucid Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lucid Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.